Mts Medications (AMEX:MPP)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Mts Medications Charts. Click Here for more Mts Medications Charts.](/p.php?pid=staticchart&s=A%5EMPP&p=8&t=15)
MTS Medication Technologies, (AMEX:MPP), an international provider of
automated packaging systems and consumable supplies designed to improve
adherence to medication regimens for senior citizens and chronically ill
patients, today announced results for its fiscal fourth quarter and year
ended March 31, 2008.
Fourth Quarter
Revenue for the fourth quarter decreased 1% to $14.2 million from $14.3
million in the prior year. Net income was $136,000, or $0.02 per diluted
common share, compared with net income of $763,000, or $0.11 per diluted
common share in the prior year.
Gross margin for the fourth quarter declined to 35.2% compared with
37.9% in the prior year’s fourth quarter. The
decrease in gross margin resulted primarily from higher factory overhead
costs. In addition, certain product quality issues resulted in a charge
of approximately $140,000 for unusable product that was returned from
customers in the UK.
SG&A expenses for the fourth quarter were $4.4 million, or 30.9% of
revenue, compared with $3.3 million, or 23.4% of revenue, in the prior
year’s fourth quarter. The increase in SG&A
expenses was primarily due to increased personnel costs, consulting
expenses and higher R&D expenditures. In addition, increased costs for
European operations were related to incremental marketing efforts.
During the fourth quarter, the Company recorded an accrual of
approximately $290,000 for unused vacation pay for all of its employees
as of March 31, 2008. As a result of this accrual, payroll expense for
the fiscal year ended March 31, 2008 includes 52 weeks of salaries and
the amount of accrued vacation pay. The Company intends to change its
vacation policy in fiscal 2009, and as a result, the fiscal year 2009
payroll expense will include 52 weeks of salary for all employees, less
the amount of accrued vacation pay, which will no longer be applicable
because of the change in vacation policy.
The operating loss in the fourth quarter was $259,000, or 1.8% of
revenue, compared with operating income of $1,472,000, or 10.3% of
revenue, in the prior year’s fourth quarter.
Operating income decreased primarily due to lower gross profits, higher
SG&A costs and increased depreciation and amortization expenses.
During the fourth quarter, the Company realized an income tax benefit
related to uncertain tax positions previously recorded. The tax benefit
was approximately $185,000 and resulted from the expiration of the
statute of limitations regarding those positions. In addition, the
Company recorded a state tax benefit of approximately $135,000, net of
Federal tax, associated with an unused net operating loss carry-forward
related to its operations in the State of Florida. Although this state
tax benefit occurred in prior fiscal years, the Company determined the
tax benefit existed during a review of its income tax provision for the
fiscal year ended March 31, 2008.
Fiscal Year
Revenue for the 2008 fiscal year increased 13.1% to a record $57.8
million, compared with $51.1 million in the prior year. Net income
available to common stockholders was $2,055,000 compared with a net loss
to common stockholders of $2,124,000 in the prior year. Net income per
diluted common share was $0.31 compared with a net loss per diluted
common share of $0.35 in the prior year. During the third quarter of the
prior year, the Company redeemed all of its outstanding shares of
convertible preferred stock and recorded a constructive dividend of $4.5
million or $0.73 per diluted common share. Net income for the fiscal
year ended March 31, 2007, before preferred stock dividends, was
$2,531,000 or $0.36 per diluted common share.
Gross margin for the fiscal year was 37.9%, the same as in the prior
year. Increased direct costs of materials and labor were generally
offset by increased selling prices. Incremental product margins realized
on increased revenue associated with consumables and prepack machines
were partially offset by higher factory overhead costs.
SG&A expenses were $15.7 million, or 27.2% of revenue, compared with
$12.5 million, or 24.4% of revenue in the prior year. SG&A expenses
increased primarily due to higher costs associated with increased
personnel, costs related to the support of automation products and
administration costs related to operations in Germany, where Consilio
GmbH was acquired in late fiscal 2007.
Operating income was $3,428,000, or 5.9% of revenue for the year,
compared with $4,544,000, or 8.9% of revenue in the prior year.
Operating profit decreased primarily due to higher SG&A expenses and
increased depreciation and amortization.
Todd E. Siegel, President and Chief Executive Officer, said, “We
believe that our position as the leader in adherence packaging solutions
for the long-term care market in the U.S. is secure, and our penetration
in Europe continues to enhance our overall financial results. Fiscal
2008 was a challenging year for MTS as we began our most significant
project to date with our largest customer to deliver state-of-the-art
automation that will allow them to meet their objectives for
streamlining and centralizing operations. As a result of this and other
initiatives, we have dedicated a substantial amount of resources to our
automation products, European infrastructure development and retail
pharmacy market initiatives. Although we began the year with the
expectation that our financial performance would reflect favorable
results, we are optimistic that the benefit we derive from delivering
new and innovative state-of-the-art technology to our core market will
more than offset the short-term effect on our financial results.
“In the past, we have said that our long-term
plan for enhanced stockholder value focuses on our commitment to grow
MTS into a much larger and diverse company. At times, that plan may
appear to be at odds with short-term expectations. Although we
understand the apparent conflict and recognize that a 30% increase in
SG&A costs, quarter over quarter, is substantial, we firmly believe that
our vision will be realized.”
Siegel continued, “We believe our investment
in packaging automation technology will provide for the continued growth
of our very profitable consumable products. The current costs associated
with a significant contract to provide our OnDemand technology to our
largest customer were greater than we anticipated. The revenue we had
originally expected to record in our fourth quarter ended March 31, 2008
associated with this agreement has been recorded in our first quarter.
Four OnDemand Express II and 3 AccuFlex machines have now been accepted.
This agreement for $14 million of equipment is expected to be completed
in fiscal 2009. Of the 24 machines to be delivered, there are currently
14 systems installed. Although the product margin is lower than usual
for our machines, we believe the benefit of having the largest pharmacy
provider in our market standardized on our technology is significant. In
the future the infrastructure that we have been investing in will allow
us to efficiently implement over $15 million annually in equipment
revenue and absorb all the costs we have built into the organization. In
addition, by the end of this fiscal year, the OnDemand machine
installations currently in place will contribute approximately $2
million annually in recurring support fees.”
Siegel concluded, “Fiscal year 2009 should
prove to be an exciting and rewarding year for MTS and our stockholders.
We continue to set the stage for transforming the Company from the
largest supplier of adherence packaging systems for the U.S. long-term
care pharmacy market into a global enterprise. We believe we will
accomplish this by continuing to serve the customers that deliver
medication adherence packaging to patients who currently obtain their
prescriptions from a wide variety of sources including the traditional
retail and mail order pharmacy channels. Our commitment to profitably
grow our company in to a global enterprise is an integral part of our
long-term plan.”
Notice of Conference Call
Management of the Company will host a conference call on Tuesday, July
1, 2008 at 8:30 AM EDT to discuss the Company’s
earnings, financial results and achievements, which will be followed by
a question and answer session with professional investors. Private
investors are encouraged to email their questions in advance of the
conference call to ir@mts-mt.com or
by facsimile to 727-579-8067.
To access the conference call, please telephone 888-459-5609 and enter
52522025 for the conference ID number. A digital replay will be
available and may be accessed by visiting the Company’s
web site at www.mts-mt.com.
About the Company
Founded in 1984, MTS Medication Technologies (www.mts-mt.com)
is an international provider of medication compliance packaging systems
designed to improve medication dispensing and administration. MTS
manufactures automated packaging machines and related consumables for
prescription medications and nutritional supplements. The Company serves
approximately 8,000 pharmacies worldwide.
This press release contains forward-looking statements within the
meaning of that term in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Additional
written or oral forward-looking statements may be made by the Company
from time to time, in filings with the Securities and Exchange
Commission or otherwise. Statements contained herein that are not
historical facts are forward-looking statements made pursuant to the
safe harbor provisions described above. Forward-looking
statements may include, but are not limited to, projections of revenue,
income or losses, the value of contracts, capital expenditures, plans
for future operations, the elimination of losses under certain programs,
financing needs or plans, compliance with financial covenants in loan
agreements, plans for sale of assets or businesses, plans relating to
products or services of the Company, assessments of materiality,
predictions of future events and the effects of pending and possible
litigation, as well as assumptions relating to the foregoing. In
addition, when used in this discussion, the words “anticipates”,
“estimates”, “expects”,
“intends”, “believes”,
“plans” and
variations thereof and similar expressions are intended to identify
forward-looking statements. In particular, all statements
regarding expectations for fiscal 2009 are forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified based on
current expectations. Consequently, future events and actual
results could differ materially from those set forth in, contemplated
by, or underlying the forward-looking statements contained herein. Statements
in the Press Release describe factors, among others, that could
contribute to or cause such differences. Other factors that could
contribute to or cause such differences include, but are not limited to,
unanticipated increases in operating costs,
changes in the United Kingdom, Germany or other European healthcare
regulatory systems healthcare regulatory system, labor disputes,
customer rejection of any installed OnDemand machine, capital
requirements, increases in borrowing costs, product demand, pricing,
market acceptance, hurricanes, intellectual property rights and
litigation, risks in product and technology development and other risk
factors detailed in the Company’s Securities
and Exchange Commission filings.
Readers are cautioned not to place undue reliance on any
forward-looking statements contained herein, which speak only as of the
date hereof. The Company undertakes no obligation to publicly
release the result of any revisions of these forward-looking statements
that may be made to reflect events or circumstances after the date
hereof or to reflect the occurrence of unexpected events.
MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2008 AND 2007
(In Thousands)
ASSETS
2008
2007
Current Assets:
Cash
$
662
$
292
Restricted Cash
158
-
Accounts Receivable, Net
8,213
9,194
Inventories, Net
14,504
5,767
Prepaids and Other
2,528
926
Deferred Tax Asset
495
271
Total Current Assets
26,560
16,450
Property and Equipment, Net
7,746
5,344
Goodwill
1,161
740
Other Intangible Assets, Net
783
808
Other Assets, Net
2,198
2,507
Total Assets
$
38,448
$
25,849
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts Payable and Accrued Liabilities
$
8,653
$
6,633
Current Maturities of Long-Term Debt
74
2,447
Current Maturities of Related Party Note Payable
106
328
Customer Deposits
4,123
391
Total Current Liabilities
12,956
9,799
Long-Term Debt, Less Current Maturities
11,691
5,395
Related Party Note Payable, Less Current Maturities
-
106
Other Liabilities
834
283
Deferred Tax Liability
376
553
Total Liabilities
25,857
16,136
Stockholders' Equity:
Common Stock
64
62
Capital In Excess of Par Value
10,137
8,736
Accumulated Other Comprehensive Income
374
254
Retained Earnings
2,344
989
Treasury Stock
(328
)
(328
)
Total Stockholders' Equity
12,591
9,713
Total Liabilities and Stockholders' Equity
$
38,448
$
25,849
MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands; Except Earnings Per Share Amounts)
Three Months Ended
Twelve Months Ended
March 31,
March 31,
2008
2007
2008
2007
Net Sales
$
14,151
$
14,288
$
57,809
$
51,095
Costs and Expenses:
Cost of Sales
9,171
8,879
35,880
31,736
Selling, General and Administrative
4,373
3,338
15,716
12,461
Depreciation and Amortization
866
599
2,785
2,354
Total Costs and Expenses
14,410
12,816
54,381
46,551
Operating (Loss) Income
(259
)
1,472
3,428
4,544
Other Expenses:
Interest Expense
136
189
637
372
(Loss) Income Before Taxes
(395
)
1,283
2,791
4,172
Income Tax (Benefit) Expense
(531
)
520
736
1,641
Net Income
136
763
2,055
2,531
Convertible Preferred Stock Dividends
-
-
-
151
Constructive Dividend Related to Redemption
of Convertible Preferred Stock
-
-
-
4,504
Net Income (Loss) Available to Common Stockholders
$
136
$
763
$
2,055
$
(2,124
)
Net Income (Loss) Per Basic Common Share
$
0.02
$
0.12
$
0.32
$
(0.35
)
Net Income (Loss) Per Diluted Common Share
$
0.02
$
0.11
$
0.31
$
(0.35
)